Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MYO vs DRIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MYO Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–4 Matrix Metrics)

MYO Overall Winner 6-Pillar Tally: MYO 4 – 1 DRIO (1 Tie) Matrix Metrics: MYO 6 – 4 DRIO

As of Nov 20, 2026, Myomo Inc. (MYO) is the stronger overall head-to-head candidate over DarioHealth Corp. (DRIO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MYO carries a Unified Composite Score of 40.1/100 (SELL) at $0.81 (N/M Forward P/E, -21.8% operating margin), whereas DRIO carries 42.2/100 (HOLD) at $1.32 (10.6x Forward P/E, -142.7% operating margin).

  • Composite vs. Pillar Nuance: While DRIO currently prints a higher short-term Unified Composite Score (42.2/100 HOLD vs. MYO 40.1/100 SELL), MYO captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-21.8% vs. -142.7% operating margin) and revenue trajectory (+22.2% vs. +6.1% YoY).
  • Technical & Structure Timing Caution: MYO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7); meanwhile DRIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MYO vs DRIO
MYO NYSE American Head-to-Head Winner
Myomo Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$0.81
-3.45% 1D
Market Cap $33.7M
TTM Revenue $46M
Forward P/E N/M
Beta / 30D Vol 2.22β · 107% Vol
Unified Composite Score
40.1 / 100 SELL
Tech 25.0 Fund 43.0 Flow 58.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 29
RSI-14: 28.7 · SMA20: $1.16 · SMA50: $1.32
DRIO NASDAQ
DarioHealth Corp. Common Stock
Surgical & Medical Instruments & Apparatus
$1.32
-8.33% 1D
Market Cap $16.3M
TTM Revenue $21M
Forward P/E 10.6x
Beta / 30D Vol 0.45β · 182% Vol
Unified Composite Score
42.2 / 100 HOLD
Tech 50.0 Fund 52.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -30.0%), weak momentum, RSI 24
RSI-14: 24.0 · SMA20: $2.34 · SMA50: $4.46

6-Pillar Scorecard Institutional Category Breakdown (MYO 4 – 1 DRIO)

Columns: Metric · MYO · DRIO
1. Valuation Multiples DRIO
Forward P/E N/M 10.6x
Trailing P/E N/M 10.6x
PEG Ratio N/M N/M
EV / Revenue 0.9x 0.8x
2. Growth & Scale MYO
Revenue Growth (YoY) +22.2% +6.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $46M $21M
Market Cap $33.7M $16.3M
3. Profitability & Quality MYO
Gross Margin 70.1% 61.3%
Operating Margin -21.8% -142.7%
Net Profit Margin -33.1% -159.9%
Return on Equity (ROE) -173.5% -46.6%
4. Balance Sheet & Cash Flow MYO
Cash Generation (TTM) -$9.1M -$28M EBITDA
Cash Flow Margin -20.0% -132.8% EBITDA Mgn
Net Cash / Leverage $8.9M Net Debt (3.44x D/E) $6.37 Book/Sh · -46.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MYO
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 266.0% (81st %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Health Information Services Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MYO (6) vs DRIO (4)
Institutional Metric MYO DRIO Criterion Row Edge
Market Capitalization
Scale
$33.7M $16.3M Larger Scale MYO
Trailing P/E Ratio
Valuation
N/M 10.6x Lower Multiple DRIO
Forward P/E Ratio
Valuation
N/M 10.6x Lower Multiple DRIO
Revenue Growth (YoY)
Growth
+22.2% +6.1% Higher Growth MYO
Operating Margin (TTM)
Profitability
-21.8% -142.7% Higher Margin MYO
Net Profit Margin
Profitability
-33.1% -159.9% Higher Margin MYO
Return on Equity (ROE)
Capital Efficiency
-173.5% -46.6% Higher ROE DRIO
52-Week Range Position
Momentum
16% ($1–$2) 2% ($1–$15) Stronger Trend MYO
Beta / 30D Volatility
Risk Regime
2.22β · 107% Vol 0.45β · 182% Vol Lower Realized Risk MYO
Unified Institutional Score
Composite Signal
40.1 / 100 (SELL) 42.2 / 100 (HOLD) Higher Composite DRIO
Trailing 12M Revenue (USD)
Operating Scale
$46M $21M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
70.1% 61.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.9x EV/Rev N/M PEG · 0.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.1M ($8.9M Net Debt (3.44x D/E)) -$28M EBITDA ($6.37 Book/Sh · -46.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MYO +27.77 pp
MYO: -33.52% · DRIO: -61.29%
3M Horizon MYO +40.04 pp
MYO: -41.65% · DRIO: -81.69%
6M Horizon MYO +61.19 pp
MYO: -22.02% · DRIO: -83.21%
1Y Horizon MYO +102.87 pp
MYO: +12.3% · DRIO: -90.57%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MYO vs DRIO. Trailing 12-month operating profitability (MYO -21.8% vs DRIO -142.7%) and valuation multiples (MYO N/M vs DRIO 10.6x Forward P/E) are benchmarked directly in Pillar 4 below.

MYO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$46M
Gross Margin70.1%
Op. Margin-21.8%
ROE / Fwd P/E-173.5% · N/M
DRIO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$21M
Gross Margin61.3%
Op. Margin-142.7%
ROE / Fwd P/E-46.6% · 10.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MYO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 266.0%
IV Percentile 81st %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MYO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DRIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DRIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MYO Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $33.7M market capitalization and -21.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DRIO Moat Profile Cyclical / Execution-Driven Positioning
Health Information Services Operator
Competes within the Health Information Services value chain with $16.3M market capitalization and -142.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MYO vs DRIO Key Questions & Quantitative Answers

As of Nov 20, 2026, Myomo Inc. (MYO) is the stronger overall head-to-head candidate over DarioHealth Corp. (DRIO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MYO carries a Unified Composite Score of 40.1/100 (SELL) at $0.81 (N/M Forward P/E, -21.8% operating margin), whereas DRIO carries 42.2/100 (HOLD) at $1.32 (10.6x Forward P/E, -142.7% operating margin). Composite vs. Pillar Nuance: While DRIO currently prints a higher short-term Unified Composite Score (42.2/100 HOLD vs. MYO 40.1/100 SELL), MYO captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-21.8% vs. -142.7% operating margin) and revenue trajectory (+22.2% vs. +6.1% YoY). Technical & Structure Timing Caution: MYO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7); meanwhile DRIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MYO leads the Growth & Scale pillar: MYO posts +22.2% YoY revenue growth and +0.0% YoY earnings growth on $46M TTM revenue (70.1% gross margin, -21.8% operating margin), compared with DRIO at +6.1% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (61.3% gross margin, -142.7% operating margin). On trailing 12-month operating scale, MYO generates $46M in USD-normalized revenue versus $21M for DRIO. In operating R&D and SG&A reinvestment, MYO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DRIO.

DRIO screens cheaper on headline valuation multiples. MYO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.9x EV/Revenue (-20.0% FCF margin), whereas DRIO trades at 10.6x Forward P/E, 10.6x Trailing P/E, N/M PEG, and 0.8x EV/Revenue (-132.8% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MYO (-173.5% ROE) versus DRIO (-46.6% ROE) capital efficiency.

In options market volatility and institutional positioning, MYO carries 266.0% implied volatility (81st %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.22β · 107% Vol realized risk). By comparison, DRIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.45β · 182% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.